Related Experiment Video
Updated: May 25, 2025
07:48
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice
Published on: October 13, 2018
7.6K
Engineered Exosomes Carrying Super-Repressor IκB Reduced Biliary Atresia-Induced Liver Fibrosis in Minipig and Mouse
Jisoo Kang1, Cheolhyoung Park2, Hanoul Yun2
1College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea.
Pharmaceutics
|February 26, 2025
Summary
Exosome therapy (Exo-SrIκB) successfully treated liver fibrosis in animal models by inhibiting Nuclear Factor-kappa B (NF-κB) signaling, offering a promising approach for chronic liver diseases.
Area of Science:
- Hepatology
- Biotechnology
- Nanomedicine
Background:
- Biliary atresia causes progressive liver damage, including fibrosis, with unclear pathogenesis.
- Nuclear Factor-kappa B (NF-κB) is a key mediator in liver inflammation and fibrosis.
- Exosome-based therapies offer targeted delivery and low immunogenicity for liver diseases.
Purpose of the Study:
- To evaluate the therapeutic potential of Exo-SrIκB for cholestatic liver fibrosis.
- To assess the efficacy of exosome-encapsulated super-repressor IκB (SrIκB) in preclinical models.
Main Methods:
- Exo-SrIκB was engineered using EXPLOR technology to load SrIκB into exosomes.
- Therapeutic efficacy was tested in minipig and mouse models of induced cholestatic liver disease.
Main Results:
- Exo-SrIκB significantly reduced liver fibrosis progression in both models.
- Inhibition of NF-κB nuclear translocation and reduced fibrotic markers (collagen, α-SMA) were observed.
- Improved hepatic function was noted in treated animals compared to controls.
Conclusions:
- Exo-SrIκB effectively suppresses NF-κB signaling, alleviating liver fibrosis.
- Exosome-based therapeutics show potential for treating liver fibrosis and other chronic liver conditions.
